The leading biologics, ADCs, & bioconjugates CDMO + CRO.

Abzena is a biopharmaceutical CDMO & CRO that provides fully integrated, tailored drug design, development and manufacturing services spanning from early discovery through commercial.

Let's work together to move medicine forward.

We enable you to bring life-changing medicines to patients in need. Let’s work together to de-risk & streamline the development and manufacture of your biologic or antibody-drug conjugate (ADC).

Let’s move you from promise to product.

Let’s work together to move medicine forward

The asset you are developing right now can make a real difference for patients in need. We offer best-in-class CDMO + CRO services along with a highly detailed and personalized experience deploying the best technologies, shortening lead times, and implementing effective risk mitigation strategies.

That means our customer’s bioconjugate, ADC or biologic programs can go from promise to product, faster.

We are advocates and partners for our customers’ success.

Your bioconjugate and biologics-focused CDMO + CRO partner with:

  • Fully integrated early R&D through commercial capabilities
  • High-quality & trusted data that drives development
  • Streamlined regulatory support tailored to your program

At Abzena we aim to start smart, and finish fast, ‘Developability’ balances the scales of an ideal drug candidate vs the challenges faced.

Biocompare.com: Addressing Antibody-Drug Conjugate Development Challenges

Abzena’s Scientific Leader and Senior Vice President, Petra Dieterich Ph.D., features in a new article on Biocompare. As part of the articles ‘Addressing Antibody-Drug Conjugate Development Challenges’ feature, Petra provided her thoughts on how ADC products still face ...
Abzena - Moving medicine forward.

Blog: Digital Brand Refresh – The Launch of a Dynamic, New Abzena.com

We are pleased to share with our customers that our new, brand refreshed, website is live. Here is a brief overview of some differences that you’ll find as you navigate our new website… At first glance, we’ve given ...
Biologics Formulation Development - Abzena

Pharmaceutical Technology: Forging Ahead in Formulation

Abzena’s Senior Manager in Analytics, Gary Watts is featured in the latest edition of Pharmaceutical Technology. As part of the articles ‘Forging Ahead in Formulation’ feature, Gary discusses how new and existing technologies, as well as a patient centric ...

Drug Discovery 2024

Connect with Abzena’s Robert Francis PhD at Drug Discovery 2024 and learn more about our latest developments in cell imaging at poster number 177 at the ELRIG conference https://elrig.org/portfolio/drug-discovery-2024/, 2nd – 3rd October. ‘Application of Real-Time Live Cell ...

Basel Lunch Seminar: Mastering the Art of Developing a Successful Bispecific Antibody

One design doesn’t fit all: The short journey to a successful bispecific therapeutic antibody Transitioning from single-functional antibodies to sophisticated bispecific designs not only introduces unique challenges for drug developers but also demands innovative approaches. Unlike traditional antibodies, bispecifics ...

16th Drug Discovery Strategic Summit

Abzena is proud to be a Gold Sponsor at the 16th Drug Discovery Strategic Summit taking place on October 9-10 2024 at the San Francisco Airport Marriott Waterfront. Vice Presidents of Business Development Sudha Krishnan and Zoe Yi Zhang welcome the ...
ADC Imaging Poster - Drug Discovery 2024

Scientific Poster: Application of Real-Time Live Cell Imaging in the Development of Antibody-Drug Conjugates

Streamlining the Development of Relative Potency Assays for ADCs - Abzena

Scientific Poster: Streamlining the Development of Relative Potency Assays for ADCs

Developability for Complex Biologics & Bioconjugates - Abzena Info Sheet

Developability For Complex Biologics & Bioconjugates

"Abzena has been crucial in advancing and validating our technology and programs. The team is very thoughtful, has strong troubleshooting skills and maintains a high standard in generating quality data with integrity. We highly recommend working with Abzena."

Shiva Bhowmik, PhD

Shiva Bhowmik, PhD | COO
TRIO Pharmaceuticals, Inc.

Explore customer testimonials
"I’ve never had a CRO project go this smoothly and the ADCs delivered were very high quality. I’m confident that my client will put Abzena at the top of their list for future ADC projects."



David Jackson

David Jackson | Pharmaceutical Consultant & ADC Expert
DYJ Pharma Consulting

Explore customer testimonials
“Throughout the development of AGX101, Abzena has worked closely with us to achieve successful GMP manufacturing and quality control. We could not have reached this milestone without Abzena’s expertise, cooperation, and support.”


Paul Jaminet

Paul Jaminet | Co-founder & CEO
Angiex

Explore customer testimonials
"We worked with the Abzena team for the design and the initial production of both the mAb and the antibody-chelator conjugate to support our R&D programs. We had a productive and valuable interaction with a highly skilled scientific team and we benefited from the flexibility of the services at this early stage of development."
Tina Bjørnlund Bønsdorff

Tina Bjørnlund Bønsdorff | CSO
Oncoinvent AS

Explore customer testimonials

5 Discovery & Manufacturing Facilities Across 3 Cities

Cambridge, UK

Development, Discovery

Abzena Cambridge specializes in the early discovery, design, and development of complex biologics and bioconjugates.

Bristol, PA, USA

Discovery, Manufacturing

At Abzena Bristol, we specialize in bioconjugation, quality linker payloads, highly potent materials and complex chemistry.

San Diego, CA, USA

Development, Manufacturing

Abzena San Diego boasts a trio of cutting-edge facilities designed to accelerate the development, production, and testing of biologics. 

Let's move medicine forward.

The leading biologics CDMO + CRO that de-risks and accelerates drug development. Let’s move medicine forward for patients in need.